Our pipeline starts with strong science; aimed at translating immunology breakthroughs into differentiated medicines.
argenx engineers first-in-class therapies for rare diseases – where underserved patients need breakthroughs and the healthcare community needs options.
Our franchise-focused approach to development has created a pipeline that is as broad as it is deep, allowing us to advance select opportunities ourselves while partnering others.
argenx has several assets that emerged from the Immunology Innovation Program that have been out-licensed to a partner for further development.
Target:IL-22R
LP0145 (ARGX-112) was designed as a SIMPLE Antibody® to block receptor, IL22R. LEO Pharma is evaluating the antibody for atopic dermatitis.
Target:MET
AgomAb Therapeutics, a privately held, venture-backed company (www.agomab.com) exclusively licensed the SIMPLE Antibody® technology to generate a set of HGF-mimetic agonists directed at the MET receptor. The lead antibody, AGMB-101 (previously referred to as ARGX-114), has the potential to regenerate damaged tissue in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
Target:GARP
ARGX-115, now known as ABBV-151, was designed as a SIMPLE Antibody® inhibitor of GARP-TGF-β1 and is being investigated by AbbVie. ARGX-115 is designed to block GARP and to reactive the immune system against tumors.
